228 related articles for article (PubMed ID: 25857011)
1. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
Kawaida H; Fujii H
Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
[No Abstract] [Full Text] [Related]
2. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
3. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
4. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
6. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
Santi I; Brandt A; Hemminki K
Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
[No Abstract] [Full Text] [Related]
7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
8. Strategies to improve the outcome in locally advanced pancreatic cancer.
Späth C; Nitsche U; Müller T; Michalski C; Erkan M; Kong B; Kleeff J
Minerva Chir; 2015 Apr; 70(2):97-106. PubMed ID: 25658301
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.
Gobbi PG; Bergonzi M; Comelli M; Villano L; Pozzoli D; Vanoli A; Dionigi P
Cancer Epidemiol; 2013 Apr; 37(2):186-90. PubMed ID: 23369450
[TBL] [Abstract][Full Text] [Related]
10. [Pancreatic cancer- a curable disease].
Limani P; Samaras P; Lesurtel M; Graf R; DeOliveira ML; Petrowsky H; Clavien PA
Praxis (Bern 1994); 2015 Apr; 104(9):453-60. PubMed ID: 25900693
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
12. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
13. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Shukla PJ
Ann Surg; 2011 Aug; 254(2):385-6; author reply 386. PubMed ID: 21677560
[No Abstract] [Full Text] [Related]
14. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
Weiss MJ; Wolfgang CL
Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
[No Abstract] [Full Text] [Related]
15. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
Venkatesan P
Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
[No Abstract] [Full Text] [Related]
16. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
17. A pancreatic cancer multidisciplinary clinic: insights and outcomes.
Schiffman SC; Abberbock S; Winters S; Valko C; Steve J; Zureikat AH; Zeh HJ; Hogg ME
J Surg Res; 2016 May; 202(2):246-52. PubMed ID: 27229097
[TBL] [Abstract][Full Text] [Related]
18. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
19. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Pancreatic Cancer.
Hogendorf P; Durczyński A; Strzelczyk J
J Invest Surg; 2018 Apr; 31(2):151-152. PubMed ID: 28267398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
